Skip to content
Theme
OnDevice Tools

Tech BusinessStart-ups & Funding

Isomorphic Labs funding reaches $5 billion for AI drug discovery

The Series C round was co-led by Greenoaks and Sequoia Capital, with backing from Andreessen Horowitz and Alphabet, as AI drug discovery attracts record investment.

Illustration of an AI drug discovery laboratory with molecular models and a funding chart

Key takeaways

  • Isomorphic Labs raised $5 billion in a Series C round.
  • Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz and Alphabet also investing.
  • The company plans to use the funds for AI models, disease research and clinical trial preparation.
  • Drug discovery start-ups raised a record $23.2 billion in 2026, according to Dealroom data cited by CNBC Technology.
In this article
  1. The funding round
  2. Investors and use of funds
  3. Hassabis and the DeepMind link
  4. AI drug discovery race
  5. Scale and next steps

The funding round

The Isomorphic Labs funding round has reached $5 billion, according to CNBC Technology. The company announced the Series C investment on 17 November 2026. It said the new capital will support work on AI-designed medicines.

The round came after Demis Hassabis stepped back as CEO of Google DeepMind. Hassabis founded Isomorphic Labs and has led it since 2021. The company was created to apply AI to drug discovery.

Investors and use of funds

Greenoaks and Sequoia Capital co-led the investment. Andreessen Horowitz also participated. Alphabet, the parent company of Google, provided funding as well.

Isomorphic Labs says the money will help it build foundational biology models. These models are meant to represent biology at a molecular level. The company also plans to deepen its understanding of disease and advance its first treatment programmes towards clinical trials. It says this work aims to deliver tangible impact for patients.

Hassabis said this belief shaped Isomorphic Labs from the start. He also said AI could speed up progress in understanding disease and developing treatments.

Illustration: Google DeepMind logo, Google logo, business, AI and the labels AI Drug Discovery, Alphabet, Demis Hassabis

Demis Hassabis co-founded DeepMind before Google acquired the AI lab in 2014. Isomorphic Labs began as a DeepMind spin-out in 2021. Hassabis has been CEO of the new company since then.

The latest funding round arrives after Hassabis reduced his role at DeepMind. CNBC Technology says he stepped back as DeepMind CEO earlier in 2026. The timing links the new investment to his shift away from that role.

AI drug discovery race

Isomorphic Labs is not alone in pursuing AI for medicine development. OpenAI and Anthropic have also put resources into AI tools for this field. In June, Anthropic said it would start an AI drug discovery programme. In April, OpenAI formed a partnership with Novo Nordisk.

Investors have poured record amounts into drug discovery start-ups in 2026. CNBC Technology cites Dealroom data showing that these companies raised $23.2 billion during the year. The figure shows how much investment has gone into AI-focused biology.

The funding environment shows that AI is being applied to scientific research. Drug discovery is one area where this is happening. Investors are backing companies that say AI can speed up the search for new treatments.

Scale and next steps

The $5 billion round is larger than the company's previous raise. Isomorphic Labs secured a $2.1 billion Series B in May. The larger round gives the company more capital to continue developing its AI drug design tools and treatment pipeline.

Isomorphic Labs says it is creating a drug design system and a set of treatment candidates with help from AI. The company aims to use these tools to produce the next wave of medicines. Its first treatment programmes are still moving towards clinical trials, according to the company.

Sources

  1. Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEOCNBC Technology

Tags

Spotted a mistake? See our corrections policy. Read how News by OnDevice works in our editorial policy.